- Tablet authorization builds upon established use of LIVMARLI oral solution in Canada
- Authorization includes oral solution and tablet formulation to support flexible dosing
- Adds brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations to Mirum’s portfolio - Topline Phase 3 results expected...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 9, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...
- 2025 net product sales of approximately $520 million (preliminary and unaudited) exceed upper end of guidance - 2026 expected global net product sales of $630...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday,...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a subscription agreement with entities associated with TCGX, an institutional investor,...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...
-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations -Anticipated to be highly synergistic with...
Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027